These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37835003)

  • 1. A Case of Giant Goiter Associated with Airway Stenosis Caused by Long-Term Intravenous Epoprostenol Therapy for Idiopathic Pulmonary Arterial Hypertension.
    Nishiura K; Nakazato K; Yokokawa T; Suzuki Y; Kurosawa Y; Wada K; Shimizu T; Oikawa M; Kobayashi A; Sugimoto K; Shakespear N; Hashimoto Y; Takeishi Y
    J Clin Med; 2023 Oct; 12(19):. PubMed ID: 37835003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.
    Menon AA; Sahay S; Braverman LE; Farber HW
    Lung; 2019 Dec; 197(6):761-768. PubMed ID: 31696306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic enlargement in a patient receiving therapy with vasodilators for pulmonary arterial hypertension: a case report.
    Someya Y; Koyasu S; Ohnishi Y; Ohno T; Shimizu H; Isoda H; Nakamoto Y
    Abdom Radiol (NY); 2022 Jun; 47(6):1948-1953. PubMed ID: 35257202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report.
    Alexandre A; Furtado I; Carvalho L; Gonçalves F; Melo A; Alves J; Santos M; Reis A
    ESC Heart Fail; 2023 Aug; 10(4):2722-2727. PubMed ID: 37336527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epoprostenol Therapy for Pulmonary Arterial Hypertension.
    Akagi S; Nakamura K; Matsubara H; Ogawa A; Sarashina T; Ejiri K; Ito H
    Acta Med Okayama; 2015; 69(3):129-36. PubMed ID: 26101188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of epoprostenol on the thyroid gland: enlargement and secretion of thyroid hormone.
    Chadha C; Pritzker M; Mariash CN
    Endocr Pract; 2009 Mar; 15(2):116-21. PubMed ID: 19289321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graves' disease presenting as bi-ventricular heart failure with severe pulmonary hypertension and pre-eclampsia in pregnancy--a case report and review of the literature.
    Sabah KM; Chowdhury AW; Islam MS; Cader FA; Kawser S; Hosen MI; Saleh MA; Alam MS; Chowdhury MM; Tabassum H
    BMC Res Notes; 2014 Nov; 7():814. PubMed ID: 25927843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful transition from intravenous epoprostenol to oral selexipag and inhaled iloprost in a case of severe pulmonary arterial hypertension associated with systemic lupus erythematosus.
    Saiki C; Kashiwado Y; Yokoyama T; Ayano M; Imabayashi K; Kawano S; Higashioka K; Kimoto Y; Fukata M; Mitoma H; Ono N; Arinobu Y; Akashi K; Horiuchi T; Niiro H
    Mod Rheumatol Case Rep; 2022 Jun; 6(2):183-188. PubMed ID: 35134204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension.
    Maki H; Yao A; Inaba T; Shiga T; Hatano M; Kinugawa K; Yamashita T; Aizawa T; Nagai R
    Int Heart J; 2011; 52(5):323-6. PubMed ID: 22008445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension.
    Tokunaga N; Ogawa A; Ito H; Matsubara H
    J Cardiol; 2016 Dec; 68(6):542-547. PubMed ID: 27005767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of pulmonary arterial hypertension with chronic hepatitis that resulted in hepatosplenomegaly after administration of prostaglandin I2.
    Goten C; Usui S; Hamaoka T; Harada T; Inoue O; Okada H; Takashima SI; Kato T; Murai H; Sakata K; Furusho H; Kawashiri MA; Takamura M
    J Cardiol Cases; 2020 May; 21(5):182-185. PubMed ID: 32373243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Goiter in a Patient with Pulmonary Arterial Hypertension Treated with Epoprostenol.
    Abughazaleh S; Safdar Z
    Case Rep Pulmonol; 2020; 2020():1617253. PubMed ID: 32082680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report.
    Chida-Nagai A; Tsujioka T; Sasaki D; Izumi G; Yamazawa H; Takeda A
    Front Pediatr; 2022; 10():909595. PubMed ID: 35783314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension.
    Budev MM; Minai OA; Arroliga AC
    Drugs Today (Barc); 2004 Mar; 40(3):225-34. PubMed ID: 15148531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
    Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.
    Bergot E; Sitbon O; Cottin V; Prévot G; Canuet M; Bourdin A; de Groote P; Rottat L; Gressin V; Jaïs X; Humbert M; Simonneau G
    Int J Cardiol; 2014 Apr; 172(3):561-7. PubMed ID: 24529947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary hypertension associated with veno-occlusive disease in systemic sclerosis: Insight into the mechanism of resistance to vasodilator.
    Tada H; Konno T; Aizu M; Yokawa J; Tsubokawa T; Fujii H; Hayashi K; Uchiyama K; Matsumura M; Kawano M; Kawashiri MA; Yamagishi M
    J Cardiol Cases; 2012 Feb; 5(1):e44-e47. PubMed ID: 30532900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children.
    Nakayama T; Shimada H; Takatsuki S; Hoshida H; Ishikita T; Matsuura H; Saji T
    Circ J; 2007 Nov; 71(11):1785-90. PubMed ID: 17965503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival of patients with pulmonary arterial hypertension recovering to World Health Organization functional class I or II: a historical comparison between intravenous epoprostenol and oral agents.
    Yamamoto K; Takeda Y; Takeda Y; Naniwa T; Narita H; Ohte N
    BMC Res Notes; 2014 Jun; 7():359. PubMed ID: 24920465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.